· Health Care Technology · S&P SmallCap 600
OMCL OMNICELL INC $1.5B
No. Medication management is described as AI-enabled. No product is named.
3 of 15
Reach, Weight, and Proof.
Last updated score 23 OctLast review 29 OctLast earnings call 29 OctNext earnings call not posted yet
What they are doing
Omnicell's annual report for the year ended 31 December 2025, filed 26 February 2026, says the company may add artificial intelligence to its products and processes. No product is named. The 30 July 2026 earnings release describes Omnicell as combining automation with AI-enabled intelligence. No workflow is named. A biography in the annual report mentions a previous employer's AI product. That is not Omnicell's work. The 29 October 2026 call, including the questions, named no dispensing or medication-decision use. The score stays 3.
Why the score
- Reach 1 not 0: the company describes AI in medication management.
- Reach 1 not 2: no named dispensing or medication decision.
- Weight 1 not 0: the earnings description claims intelligence in the product, not only a risk sentence.
- Weight 1 not 2: no model we can point at.
- Proof 1 not 2: no program is named.
What would move it next quarter: A named use in dispensing or the medication decision.
Open these first
Evidence
Omnicell says it may incorporate artificial intelligence into certain products, services, and processes. No product that uses it is named. The risk language is about what could happen, not a live workflow.
The company description says Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence. No product and no workflow are named.